[Dr. Gabriele Testaverde, Dr Bonaria Corraduzza , ASL. N.1, SASSARI]
The therapy of the forms of ASCUS, and of cellular anomalies referable to the low-grade HPV virus to today is normally based on the use of immunostimulants; in variable percentages we observe a spontaneous negativization, independent of particular therapeutic strategies. The aim of the monocentric study was to evaluate the ability to negativize a high percentage of pap-positive women with low grade HPV, with preparation with Ozoile® (ozonized oil in oleic acid and vitamin E).
Papilloma Virus * (HPV), a genus of the Papovavirus family, is a widespread pathogenic human virus that is transmitted by sexual means. The infection can cause the onset of diseases of the skin and mucous membranes. An example is a cervical lesion. Most of these cervical lesions heal spontaneously, but some, if left untreated, progress slowly towards tumors (cervix carcinoma).
Method and overview
In oncological gynecology clinics, located at the ASL N.1 of Sassari (San Camillo Hospital), diagnostic tests (Pap tests) and vaccinations are carried out on the female population interested in the prevention of cervical cancer caused by the virus HPV (high risk genotypes).
Results
In the period between May 2017 and March 2018, about 30 patients were recruited, who due to the required characteristics, were identified as suitable for the use of Vulvovagi®Spray, provided free of charge for the period in question (approximately 5-6 months, maximum period elapsed from the first to the second pap test). 90% of the women treated were negativized. No adverse reactions or side effects have been reported.
Comments
In addition to the already known properties, which were also confirmed in this study, it was possible to observe how Vulvovagi®spray was an excellent routine therapy in low-risk positive HPV women, obtaining 90% negativity of the same at controls. Further studies can demonstrate which mechanisms of action are responsible for this result.
Zobacz także: www.ozonoterapia-med.pl